Enjoei SA

Enjoei SA maintains a strong liquidity position, with cash and equivalents amounting to BRL 224.3 million, representing 50.5% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, with a current ratio of 3.4, indicating a solid ability to meet short-term obligations. However, the company reported negative operating income of BRL 13.9 million and a net loss of BRL 9.8 million, suggesting operational inefficiencies. Profitability metrics are below industry norms, with a return on equity (ROE) of -2.96% and a return on assets (ROA) of -2.21%. These figures indicate that the company is not generating returns that meet the cost of capital, which is a concern for investors. Gross profit of BRL 33.4 million represents 54.3% of revenue, but this is offset by high operating expenses. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks. The valuation snapshot does not provide segment-specific revenue breakdowns, but the absence of geographic diversification is a red flag for long-term stability. Growth trajectory is mixed, with reported revenue of BRL 61.5 million in the latest period, compared to an analyst estimate of BRL 263.96 million. This discrepancy suggests either a significant underperformance or a misalignment in expectations. The company's capital expenditure of BRL 13.9 million indicates ongoing investment, but the negative free cash flow of BRL 16.1 million suggests that these investments are not yet generating returns. Risk factors include a low liquidity risk and low dilution potential, with no immediate filing-based flags detected. However, the negative net income and operating income raise concerns about the company's ability to sustain operations without external financing. The company's debt-to-equity ratio of 0.08 is low, but the negative free cash flow could pressure liquidity in the future. Recent events include the latest financial filing, which shows a significant revenue shortfall against analyst estimates. No recent earnings call transcripts or major regulatory filings were identified in the available data. The company's financial health appears to be deteriorating, with no clear turnaround strategy outlined in the available documentation.